NYSE:PEN - Penumbra Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$127.00 +2.00 (+1.60 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$125.00
Today's Range$124.60 - $127.40
52-Week Range$82.55 - $167.35
Volume199,000 shs
Average Volume329,868 shs
Market Capitalization$4.32 billion
P/E Ratio-12,700.00
Dividend YieldN/A
Beta0.15
Penumbra logoPenumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:PEN
CUSIPN/A
Phone510-748-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio7.90
Quick Ratio5.94

Price-To-Earnings

Trailing P/E Ratio-12,700.00
Forward P/E Ratio470.37
P/E Growth23.72

Sales & Book Value

Annual Sales$333.76 million
Price / Sales13.08
Cash Flow$0.1242 per share
Price / Cash1,022.80
Book Value$11.80 per share
Price / Book10.76

Profitability

EPS (Most Recent Fiscal Year)($0.01)
Net Income$4.65 million
Net Margins7.19%
Return on Equity2.78%
Return on Assets2.35%

Miscellaneous

Employees1,700
Outstanding Shares34,380,000
Market Cap$4.32 billion

Penumbra (NYSE:PEN) Frequently Asked Questions

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) issued its earnings results on Tuesday, August, 7th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The company earned $109.64 million during the quarter, compared to analysts' expectations of $102.24 million. Penumbra had a net margin of 7.19% and a return on equity of 2.78%. View Penumbra's Earnings History.

When is Penumbra's next earnings date?

Penumbra is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Penumbra.

What price target have analysts set for PEN?

6 analysts have issued 1-year price targets for Penumbra's shares. Their forecasts range from $145.00 to $180.00. On average, they anticipate Penumbra's share price to reach $162.50 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for Penumbra.

What is the consensus analysts' recommendation for Penumbra?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.

What are Wall Street analysts saying about Penumbra stock?

Here are some recent quotes from research analysts about Penumbra stock:
  • 1. Canaccord Genuity analysts commented, "We followed up with management this morning and discerned several noteworthy details about the firm’s newest aspiration system. PEN’s newest aspiration catheter includes three critical improvements and upgrades to PEN’s own ACE 68 catheter, further distancing and differentiating PEN from the competition in clot aspiration within the acute ischemic stroke market, in our view: 1. Larger diameter – JET 7 has the largest internal diameter of any aspiration catheter ever cleared – 0.72 inner diameter compared to PEN’s previous 0.68 catheter (Ace 68) – with JET 7’s larger diameter driving a significant increase in the number of cases in which the entire is able to be aspirated almost immediately (within 1-2 minutes)." (8/20/2018)
  • 2. According to Zacks Investment Research, "Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. " (8/11/2018)

Who are some of Penumbra's key competitors?

Who are Penumbra's key executives?

Penumbra's management team includes the folowing people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 56)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 40)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 57)
  • Mr. Daniel Donen Davis, Chief Commercial Officer & Pres of North America (Age 40)

Has Penumbra been receiving favorable news coverage?

Press coverage about PEN stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Penumbra earned a coverage optimism score of 0.15 on Accern's scale. They also gave news articles about the company an impact score of 48.43 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Penumbra.

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (13.76%), BlackRock Inc. (4.46%), Morgan Stanley (2.07%), Putnam Investments LLC (1.91%), Baillie Gifford & Co. (1.81%) and Partner Fund Management L.P. (1.67%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, FMR LLC, Waddell & Reed Financial Inc., Partner Fund Management L.P., Schwab Charles Investment Management Inc., Russell Investments Group Ltd. and Victory Capital Management Inc.. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.

Which major investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Paloma Partners Management Co, Jane Street Group LLC, Cubist Systematic Strategies LLC, Los Angeles Capital Management & Equity Research Inc., Dimensional Fund Advisors LP and Baillie Gifford & Co.. View Insider Buying and Selling for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $127.00.

How big of a company is Penumbra?

Penumbra has a market capitalization of $4.32 billion and generates $333.76 million in revenue each year. The company earns $4.65 million in net income (profit) each year or ($0.01) on an earnings per share basis. Penumbra employs 1,700 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]


MarketBeat Community Rating for Penumbra (NYSE PEN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel